Clinical Report: Timely Identification of X-linked Alport Syndrome in a Child
Overview
This case study highlights the early diagnosis of X-linked Alport syndrome (XLAS) in a 4-year-old girl, emphasizing the critical roles of genetic testing and renal biopsy in cases of persistent hematuria. The identification of a pathogenic COL4A5 variant underscores the potential for early intervention to delay progression to end-stage kidney disease.
Background
Alport syndrome (AS) is a prevalent hereditary kidney disorder caused by mutations in genes encoding the α3–α5 chains of type IV collagen. It is characterized by hematuria, proteinuria, and progressive renal failure. Early diagnosis is crucial as timely interventions can significantly delay the onset of end-stage kidney disease. Genetic testing is vital for confirming the diagnosis and guiding management, especially in families with a history of renal disease.
Data Highlights
No numerical data or trial data presented in the article.
Key Findings
['The patient was diagnosed with X-linked Alport syndrome after presenting with persistent microscopic hematuria.', 'A heterozygous missense variant in COL4A5 (c.1633G > A, p.Gly545Ser) was identified, inherited from her mother.', 'Family history indicated that the maternal grandmother had developed end-stage renal disease, highlighting the hereditary nature of the condition.', 'Early renal biopsy and genetic analysis facilitated the expedited diagnosis and treatment of the patient.', 'The report emphasizes that females with the COL4A5 variant may develop renal failure, contrary to the belief that they are merely asymptomatic carriers.']
Clinical Implications
Clinicians should consider genetic testing in pediatric patients with a family history of renal disease and persistent hematuria. Early intervention with ACE inhibitors can significantly delay the progression of renal failure in patients diagnosed with Alport syndrome.
Conclusion
This case underscores the importance of early identification and management of X-linked Alport syndrome to prevent progression to end-stage kidney disease. Genetic testing is essential for accurate diagnosis and guiding treatment strategies.
Originally Broadcast: Thursday, November 9, 2023 6:00 - 7:30 PM EST - This program is intended for Hematologists, Oncologists, Pharmacists, Pathologists, and other healthcare professionals that care for cancer patients.
